Table 1 The demographic and clinical characteristics.
ATO | ATO ≤ 2d | 2 d < ATO ≤ 4d | ATO > 4d | P-value | P-value* |
|---|---|---|---|---|---|
N | 443 | 726 | 566 | ||
Age (year) | 79.39 ± 6.74 | 79.25 ± 6.87 | 79.22 ± 6.79 | 0.92 | 0.89 |
Sex | 0.50 | – | |||
Male | 127 (28.7%) | 203 (28.0%) | 175 (30.9%) | ||
Female | 316 (71.3%) | 523 (72.0%) | 391 (69.1%) | ||
ATO (d) | 1.91 ± 0.29 | 3.51 ± 0.50 | 6.78 ± 2.50 | < 0.01 | < 0.01 |
Injury mechanism | 0.29 | – | |||
Falling | 426 (96.2%) | 709 (97.7%) | 545 (96.3%) | ||
Accident | 13 (2.9%) | 16 (2.2%) | 16 (2.8%) | ||
Other | 4 (1.0%) | 1 (0.1%) | 5 (0.9%) | ||
Fracture classification | 0.40 | – | |||
Intertrochanteric fracture | 282 (63.7%) | 434 (59.8%) | 342 (60.4%) | ||
Femoral neck fracture | 161 (36.3%) | 292 (40.2%) | 224 (39.6%) | ||
aCCI | 4.06 ± 1.03 | 4.15 ± 1.07 | 4.32 ± 1.13 | < 0.01 | < 0.01 |
Hypertension | 195 (44.0%) | 374 (51.5%) | 307 (54.2%) | < 0.01 | – |
Diabetes | 65 (14.7%) | 140 (19.3%) | 138 (24.4%) | < 0.01 | – |
CHD | 202 (45.6%) | 349 (48.1%) | 329 (58.1%) | < 0.01 | – |
Arrhythmia | 118 (26.6%) | 196 (27.0%) | 212 (37.5%) | < 0.01 | – |
Hemorrhagic stroke | 8 (1.8%) | 15 (2.1%) | 7 (1.2%) | 0.5 | – |
Ischemic stroke | 125 (28.2%) | 216 (29.8%) | 188 (33.2%) | 0.20 | – |
Cancer | 9 (2.0%) | 17 (2.3%) | 21 (3.7%) | 0.19 | – |
Associated injuries | 27 (6.1%) | 56 (7.7%) | 42 (7.4%) | 0.57 | – |
Dementia | 16 (3.6%) | 26 (3.6%) | 25 (4.4%) | 0.71 | – |
COPD | 17 (3.8%) | 38 (5.2%) | 42 (7.4%) | 0.04 | – |
Hepatitis | 11 (2.5%) | 18 (2.5%) | 21 (3.7%) | 0.36 | – |
Gastritis | 5 (1.1%) | 10 (1.4%) | 11 (1.9%) | 0.54 | – |
Treatment strategy | 0.21 | – | |||
ORIF | 281 (63.4%) | 441 (60.7%) | 341 (60.3%) | ||
HA | 157 (35.4%) | 262 (36.1%) | 213 (37.6%) | ||
THA | 5 (1.1%) | 23 (3.2%) | 12 (2.1%) | ||
Time to admission (h) | 103.70 ± 330.52 10 (1–5040) | 76.18 ± 205.61 9 (1–2160) | 68.05 ± 178.58 13 (1–2880) | 0.05 | 0.21 |
Time to chemoprophylaxis after admission (h) | 4 (1–7) | 5 (1–9) | 4 (1–8) | 0.99 | 0.96 |
Chemoprophylaxis | 0.44 | – | |||
Enoxaparin sodium | 171 (38.6%) | 266 (36.6%) | 210 (37.1%) | ||
Nadroparin calcium | 164 (37.0%) | 260 (35.8%) | 215 (38.0%) | ||
Dalteparin sodium | 66 (14.9%) | 114 (15.7%) | 95 (16.8%) | ||
Other | 42 (9.5%) | 86 (11.8%) | 46 (8.1%) | ||
Mechanical thromboprophylaxis | 0.60 | – | |||
Venous foot pumps | 89 (20.0%) | 164 (22.6%) | 122 (21.5%) | ||
Lower extremities Intermittent pneumatic compression | 354 (80.0%) | 562 (77.4%) | 444 (78.5%) | ||
Operation time (mins) | 90.11 ± 31.87 | 93.09 ± 32.55 | 97.74 ± 38.37 | < 0.01 | < 0.01 |
Blood loss (mL) | 226.60 ± 149.28 | 242.20 ± 138.91 | 240.19 ± 163.28 | 0.21 | 0.03 |
Infusion (mL) | 1566.93 ± 381.91 | 1573.95 ± 374.84 | 1621.19 ± 382.30 | 0.04 | 0.08 |
Transfusion (U) | 0.86 ± 1.19 | 0.93 ± 1.19 | 0.98 ± 1.26 | 0.25 | 0.27 |
Preoperative DVT | 142 (32.1%) | 200 (27.6%) | 201 (35.5%) | < 0.01 | – |
